EMERSON ELECTRIC (EMR) Company Report

Emerson delivered $4.3B in Q1 sales, with 2% underlying sales growth and $1.46 adjusted EPS.
Adjusted segment EBITA margin was 27.7%, and free cash flow totaled $602M (13.9% margin).
Underlying orders grew 9% YoY, and annual contract value (ACV) reached $1.6B, up 9%.
Raised full-year 2026 guidance to ~5.5% sales growth (~4% underlying), ~28% adjusted EBITA margin, and $6.40–$6.55 adjusted EPS; plans ~$1B share repurchase and 5% dividend increase.

3 days ago

Presentation

Emerson reports Q1 2026 results

EMR

Earnings

Guidance Update

Share Buyback

Robust demand drove underlying orders up 9% year-over-year in Q1, marking four consecutive quarters of double-digit order growth.
Underlying sales rose 2% YoY, with an adjusted segment EBITDA margin of 27.7% and adjusted EPS of $1.46.
Annual Contract Value of software expanded 9% to $1.6 billion, reflecting continued strength in subscription-based offerings.
Emerson reaffirmed 2026 guidance: 5.5% sales growth, 4% underlying sales growth, ~28% EBITDA margin, and raised adjusted EPS to $6.40–$6.55.
Returned capital to shareholders via $250 million of share repurchases in Q1, part of a plan to deliver approximately $2.2 billion in dividends and buybacks.

3 days ago

Transcript

Emerson reports Q1 2026 results

EMR

Earnings

Guidance Update

Share Buyback

Underlying orders grew 9% in Q1, with backlog at $7.9 billion (up 9% yoy) and a book-to-bill of 1.13.
Underlying sales rose 2% yoy; test & measurement increased 11% and Ovation accelerated 20%; adjusted segment EBITDA margin was 27.7%, and adjusted EPS was $1.46.
Software Annual Contract Value reached $1.6 billion (up 9% yoy); next-generation Nigel AI and DeltaV version 16 were released to enhance software-enabled automation.
Completed $250 million of share repurchases in Q1; reaffirmed full-year guidance of 5.5% sales growth, ~28% EBITDA margin, and raised EPS to $6.40–$6.55; targeting $2.2 billion in shareholder returns.
Regional demand remained robust in North America, India, and the Middle East & Africa, while Europe and China continued to soften.

3 days ago

Transcript

Emerson reports Q1 2026 results

EMR

Earnings

Guidance Update

Share Buyback

Underlying orders grew 9%, and underlying sales increased 2% year-over-year.
Adjusted segment EBITDA margin was 27.7%, with adjusted EPS of $1.46, up 6% year-over-year.
Annual Contract Value of software reached $1.6 billion, up 9% year-over-year.
Free cash flow of $602 million (14% margin) and $250 million of share repurchases executed in Q1.
Full-year guidance reiterated: 5.5% sales growth (4% underlying), 28% EBITDA margin, $6.40–$6.55 EPS; Q2 EPS guided at $1.50–$1.55.

3 days ago

Transcript

Emerson reports Q1 2026 results and updates 2026 outlook

EMR

Earnings

Guidance Update

Dividends

Emerson reported Q1 FY2026 net sales of $4.346 billion (up 4% yoy), with underlying orders growth of 9% and underlying sales up 2%.
GAAP EPS was $1.07, and adjusted EPS was $1.46, increases of 5% and 6% year-over-year, respectively.
Q1 operating cash flow was $699 million and free cash flow was $602 million.
The quarterly dividend was set at $0.555 per share, payable March 10, 2026; Emerson plans to return ~$2.2 billion in 2026 through ~$1.0 billion in share repurchases and ~$1.2 billion in dividends.
For fiscal 2026, the company expects ~5.5% net sales growth, adjusted EPS of $6.40–$6.55, operating cash flow of $4.0–$4.1 billion, and free cash flow of $3.5–$3.6 billion.

3 days ago

8-K

Emerson reports Q1 2026 earnings and updates full-year guidance

EMR

Earnings

Guidance Update

Dividends

Emerson posted $4.346 billion in net sales in Q1 FY2026, up 4% year-over-year, with adjusted EPS of $1.46, a 6% increase.
The board declared a $0.555/share quarterly dividend payable March 10, 2026.
Fiscal 2026 guidance raised to ~5.5% net sales growth and $6.40–$6.55 in adjusted EPS.
Capital return includes ~$1 billion in share repurchases and $1.2 billion in dividends for FY 2026.

3 days ago

Press Release

Emerson AGM 2026 approves directors and compensation, rejects board declassification

EMR

Proxy Vote Outcomes

M&A

136th Annual Meeting of Shareholders held on February 3, 2026; a quorum was achieved with 495.4 million shares (88% of outstanding) represented in person or by proxy.
Shareholders voted on four proposals: election of three incumbent directors, advisory approval of FY 2025 executive compensation, ratification of KPMG LLP as independent auditor, and amendment to declassify the board.
All three director nominees elected, executive compensation approved by ~90%, and KPMG ratification approved by ~92%, while the proposal to declassify the board failed to reach the 85% threshold.
Executive review highlighted FY 2025 results: sales +3%, operating cash flow +11%, free cash flow +12%, EPS +43%, completion of Aspen Technology and National Instruments acquisitions, and Copeland divestiture.

3 days ago

Transcript

Emerson AGM 2026: board elections approved, declassification amendment fails

EMR

Proxy Vote Outcomes

M&A

A quorum was established with 88% of outstanding shares represented, enabling the meeting to proceed.
Incumbents Martin Craighead, Gloria Flach, and Matthew Levatich were re-elected to three-year terms by a substantial majority.
An advisory vote on 2025 executive compensation passed with ~90% support, and the Audit Committee’s appointment of KPMG was ratified with ~92% in favor.
The proposal to declassify the board did not reach the required 85% approval threshold and thus failed.
Emerson highlighted its transformation via the acquisition of Aspen Technology, integration of National Instruments, and the divestiture of Copeland, aligning its automation portfolio with long-term trends.

3 days ago

Transcript

Emerson holds AGM 2026, re-elects directors and fails board declassification vote

EMR

Proxy Vote Outcomes

M&A

Auditor Change

At the 136th Annual Meeting, shareholders re-elected incumbents Martin Craighead, Gloria Flach and Matthew Levatich to three-year terms by a substantial majority.
Advisory vote on FY 2025 executive compensation was approved by approximately 90%, and ratification of KPMG LLP as auditor for FY 2026 passed with ~92%, while the proposal to declassify the board failed to reach the required 85% threshold.
The company reported FY 2025 results of sales +3%, operating cash flow +11%, free cash flow +12%, EPS +43% and adjusted EPS +9%, and highlighted acquisitions of Aspen Technology and National Instruments coupled with the divestiture of Copeland to strengthen its automation portfolio.
Final vote tabulations will be filed on Form 8-K within four business days post-meeting.

3 days ago

Transcript

Emerson outlines autonomous future strategy and 2028 targets

EMR

Guidance Update

Share Buyback

At its 2025 Investor Conference, Emerson positioned itself as a global automation leader focused on engineering the autonomous future through innovation and a software-defined technology stack.
Introduced a through-the-cycle value creation framework targeting 4–7% organic sales growth, 40% incremental margins, 10% adjusted EPS growth, and 18–20% free cash flow margin.
Set 2028 financial targets of $21 billion in net sales (5% organic CAGR), 30% adjusted segment EBITA margin, $8.00 adjusted EPS (10% CAGR), and $12 billion cumulative free cash flow, with plans to return $10 billion to shareholders.
Reiterated its 2026 Q1 and full-year outlook as previously provided on November 5, 2025.